AEHR three-lens brief
Evidence-based stock research on AEHR. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Negative free cash flow last quarterly (-$1.96M).
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 39.6pp over 30 days.
- Analyst mean target $130.00 — 39% above current (4 analysts).
- Negative free cash flow last quarterly (-$1.96M).
- Earnings scheduled 2026-10-05.
AEHR closed at $93.81 (-1.83%) as of 2026-09-11. Market cap: $3.06B. P/E (trailing) 19.8. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 39.6pp over 30 days.. Concerns: negative free cash flow last quarterly (-$1.96M).. Last quarter: Revenue $18.84M, net income $1.39M, free cash flow -$1.96M. Watching for: 2026-10-05 earnings release (24 days out).
Why three lenses on AEHR, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AEHRacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AEHR" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AEHR brief"></iframe>